Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Xanthine Oxidase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Xanthine Oxidase. Displaying page 1 of 1.
    EudraCT Number: 2013-002702-30 Sponsor Protocol Number: ALXN1101-MCD-202 Start Date*: Information not available in EudraCT
    Sponsor Name:Origin Biosciences, Inc.
    Full Title: A PHASE 2/3, MULTICENTER, MULTINATIONAL, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALXN1101 IN NEONATES WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A
    Medical condition: Molydenum CoFactor Deficiency (MoCD) Type A
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10069687 Molybdenum cofactor deficiency PT
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) IT (Prematurely Ended) NO (Completed)
    Trial results: View results
    EudraCT Number: 2013-002701-56 Sponsor Protocol Number: ALXN1101-MCD-201 Start Date*: 2014-04-16
    Sponsor Name:Origin Biosciences, Inc.
    Full Title: A Phase 2, multicenter, multinational, open-label, dose-escalation study to evaluate the safety and efficacy of ORGN001 (formerly ALXN1101) in pediatric patients with Molybdenum Cofactor Deficiency...
    Medical condition: Molybdenum Cofactor Deficiency (MoCD) Type A
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10069687 Molybdenum cofactor deficiency PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-003541-17 Sponsor Protocol Number: ALMU_2011 Start Date*: 2011-11-22
    Sponsor Name:Instituo de Investigacion Sanitaria La Fe
    Full Title: EFFECT OF THE ADMINISTRATION OF ALLOPURINOL ON THE PREVENTION OF MUSCLE MASS LOSS IN IMMOBILIZED SUBJECTS.
    Medical condition: Immobilized subjects.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-003081-42 Sponsor Protocol Number: Jus002 Start Date*: 2005-10-06
    Sponsor Name:University of DUndee
    Full Title: EXPLORING THE THERAPEUTIC POTENTIAL OF XANTHINE OXIDASE INHIBITORS IN CORONARY ARTERY DISEASE
    Medical condition: Ishaemic heart disease; Angina, acute myocardial infarction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001191-30 Sponsor Protocol Number: RDEA594-401 Start Date*: 2017-09-27
    Sponsor Name:Ironwood Pharmaceuticals, Inc.
    Full Title: A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lesinurad 200 mg in Combination With a Xanthine Oxidase Inhibitor (XOI), Compared W...
    Medical condition: Gout and moderate renal impairment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10018627 Gout PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001669-33 Sponsor Protocol Number: tsa1 Start Date*: 2005-12-09
    Sponsor Name:Greater Glasgow NHS Health Board / University of Glasgow co-sponsorship
    Full Title: New therapeutic targets in stroke prevention: the effect of allopurinol on the cerebral vasculature of patients with subcortical stroke
    Medical condition: Subcortical Ischaemic Stroke
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-003756-39 Sponsor Protocol Number: RDEA594-303 Start Date*: 2012-04-10
    Sponsor Name:Ardea Biosciences, Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects with Gout and an Intolerance or...
    Medical condition: Gout
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10018627 Gout PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001670-27 Sponsor Protocol Number: CSO1 Start Date*: 2005-11-14
    Sponsor Name:Greater Glasgow NHS Health Board / University of Glasgow co-sponsorship
    Full Title: Reversibility of cerebrovascular endothelial dysfunction in diabetes: the role of allopurinol.
    Medical condition: Type Two Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001640-56 Sponsor Protocol Number: PI12/01866 Start Date*: 2014-01-31
    Sponsor Name:Fundación Para la Investigación Biomédica de Córdoba
    Full Title: Crossover clinical trial, randomized, double blind, placebo controlled trial. Modulation of cellular mediators and repair endothelial damage in patients with chronic renal disease through inhibitio...
    Medical condition: Patients with chronic kidney disease and asymptomatic hyperuricemia on the balance of mechanisms of vascular injury and repair.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004611-21 Sponsor Protocol Number: NOM001 Start Date*: 2008-12-29
    Sponsor Name:University of Dundee
    Full Title: Does allopurinol (a xanthine oxidase inhibitor) have clinically useful anti-ischaemic effects in angina pectoris? - A randomised, double-blind, placebo-controlled trial
    Medical condition: Angina Pectoris
    Disease: Version SOC Term Classification Code Term Level
    8.1 10002383 Angina pectoris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-008485-12 Sponsor Protocol Number: eb/lm/let390/ln950/20038 Start Date*: 2009-07-01
    Sponsor Name:University of Dundee
    Full Title: Do Xanthine Oxidase Inhibitors Regress Left ventricular Hypertrophy in Diabetes?
    Medical condition: Diabetes Left Ventricular Hypertrophy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012602 Diabetes mellitus (incl subtypes) HLT
    9.1 10049773 Left ventricular hypertrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-008479-32 Sponsor Protocol Number: SR001 Start Date*: 2009-06-09
    Sponsor Name:University of Dundee
    Full Title: Do xanthine oxidase inhibitors reduce left ventricular hypertrophy and endothelial dysfunction in normotensive patients with chronic stable angina?
    Medical condition: Left ventricular hypertrophy Normotensive Chronic stable angina
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049773 Left ventricular hypertrophy LLT
    9.1 10049194 Stable angina pectoris LLT
    9.1 10005754 Blood pressure normal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003404-39 Sponsor Protocol Number: JBR-2-2013 Start Date*: 2014-01-03
    Sponsor Name:Department of Medical Research, Regional Hospital Holstebro
    Full Title: The effect of sodium nitrite infusion on renal variables, brachial and central blood pressure during enzyme inhibition by allopurinol, enalapril or acetazolamid in healthy subjects. A randomized, d...
    Medical condition: The normal physiological responses in healthy subjects
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10022891 Investigations SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004235-77 Sponsor Protocol Number: XILO-FIST Start Date*: 2015-01-02
    Sponsor Name:NHS Greater Glasgow & Clyde [...]
    1. NHS Greater Glasgow & Clyde
    2. University of Glasgow
    Full Title: Xanthine oxidase inhibition for improvement of long-term outcomes following ischaemic stroke and transient ischaemic attack (XILO-FIST).
    Medical condition: Ischaemic stroke or transient ischaemic attack (TIA) (ICD Classification Code I63.0-9 and G45.0-1)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    21.1 10029205 - Nervous system disorders 10044390 Transient ischaemic attack PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2007-004760-49 Sponsor Protocol Number: MK001 Start Date*: 2008-01-02
    Sponsor Name:University of Dundee
    Full Title: Do Xanthine Oxidase Inhibitors reduce both Left Ventricular Hypertrophy and Vascular Dysfunction in Cardiovascular patients with Renal Dysfunction?
    Medical condition: Chronic Kidney Disease Stage 3 Left Ventricular Hypertrophy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025164 LVH LLT
    9.1 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004469-32 Sponsor Protocol Number: CC-5013-CLL-001 Start Date*: 2007-02-23
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 1/2, MULTI-CENTER,OPEN LABEL STUDY OF THE SAFETY AND EFFICACY OF A STEPWISE DOSE-ESCALATION SCHEDULE OF LENALIDOMIDE MONOTHERAPY IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL CHRONIC LYMP...
    Medical condition: For the treatment of relapsed or refractory B-CLL.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003946 B-Lymphocytic, CLL (Kiel Classification) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004613-14 Sponsor Protocol Number: VERITA_PALG-CLL5 Start Date*: 2021-10-31
    Sponsor Name:POLISH ADULT LEUKEMIA GROUP
    Full Title: A prospective, multicenter, phase II trial to assess the efficacy and safety of MRD-driven treatment with VEnetoclax and RItuximab combination in previously unTreated pAtients with chronic lymphocy...
    Medical condition: Chronic lymphocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:11:46 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA